Anti-inflammatory effects of natural polysaccharides: molecular mechanisms and nanotherapeutic applications

Jihao Yang, Kai Xiong, Tianrui Li, M Zhang, Zhangyun Li, Zhili Wen, Yuchuan JiangFrontiers in Immunology 2025 · DOI

TL;DR

Chronic inflammation is a root cause of many diseases, and while natural polysaccharides show promise as anti-inflammatory agents, their poor bioavailability limits their effectiveness. This review highlights how nanonization can overcome these limitations, enhancing polysaccharide delivery and efficacy, and outlines the path towards clinical translation of these promising therapies.

What Problem Does This Paper Address?

The paper tackles the challenge of treating chronic inflammatory diseases, which are driven by persistent, excessive inflammation. While conventional anti-inflammatory therapies have significant drawbacks like drug resistance, safety risks, and poor targeting, natural polysaccharides offer a low-toxicity, biodegradable alternative. However, their clinical utility is hampered by poor water solubility and susceptibility to digestive enzymes, leading to low bioavailability. This review aims to bridge the gap between the potential of natural polysaccharides and their practical application by exploring how nanonization can enhance their therapeutic properties and discussing their clinical translation.

Methods

This paper is a comprehensive review, not an experimental study. It synthesizes existing research by:

  • Clarifying fundamental mechanisms: Detailing how inflammation occurs and how polysaccharides interact with key signaling pathways (NF-κB, MAPK, TLR, Nrf2/HO-1) and immune cells.
  • Analyzing polysaccharide activities: Linking the anti-inflammatory effects of various natural polysaccharides to their specific structural characteristics (molecular weight, monosaccharide composition, glycosidic bonds, sulfation degree).
  • Exploring nanonization strategies: Explaining how encapsulating polysaccharides in nanoparticles improves their dispersibility, stability, targeting (passive via EPR effect, active via ligand modification), and overall bioavailability.
  • Evaluating clinical translation potential: Discussing the current status of clinical trials, challenges, and future directions for polysaccharide-based therapies.

Datasets

Not discussed in the paper. This is a review article synthesizing existing literature.

Key Insights and Ideas

  • Structure-Activity Relationship is Key: The specific chemical structure of a polysaccharide (e.g., molecular weight, sulfation degree, monosaccharide composition) dictates its anti-inflammatory mechanism and efficacy. This isn't a one-size-fits-all situation.
  • Nanonization is a Game-Changer: Simply using polysaccharides isn't enough. Encapsulating them in nanoparticles dramatically improves their solubility, protects them from degradation, and allows for targeted delivery, unlocking their full therapeutic potential.
  • Synergy is Powerful: Combining polysaccharides with traditional drugs or probiotics can lead to synergistic effects, reducing the required dosage of individual components and improving overall outcomes.
  • Beyond Immune Cells: Polysaccharides can also positively influence non-immune cells (like endothelial cells and fibroblasts) to improve the inflammatory microenvironment, offering a more holistic approach to treatment.

Key Results

The paper doesn't present novel experimental results but synthesizes findings from numerous studies:

  • Natural polysaccharides can effectively regulate core inflammatory pathways like NF-κB and MAPK, and downregulate pro-inflammatory cytokines (TNF-α, IL-1β, IL-6).
  • Nanonization significantly enhances polysaccharide bioavailability, aqueous dispersibility, and targeting efficiency.
  • Specific structural features of polysaccharides, such as molecular weight and degree of sulfation, are critical determinants of their anti-inflammatory activity. For instance, low molecular weight combined with high sulfation often leads to stronger activity.
  • Polysaccharide-based nanocarriers have shown promise in animal models for various inflammatory diseases, including IBD, arthritis, and liver disease.

Limitations and Future Work

The authors acknowledge several limitations and propose future directions:

  • Structure-Activity Relationship Gaps: While progress has been made, a deeper understanding of how subtle structural differences (e.g., sulfate substitution sites) impact receptor binding and signaling is needed.
  • Animal Model Limitations: Current animal models may not fully replicate the complex human intestinal environment, leading to potential inaccuracies in predicting drug delivery and efficacy.
  • Long-Term Safety and Immunogenicity: The long-term toxicity and potential for immune activation of nanopolysaccharides require more extensive investigation.
  • Industrial Scale-Up: Challenges remain in standardizing production, ensuring batch-to-batch consistency, and meeting regulatory requirements for nanocarrier manufacturing.
  • Future Directions:
    • Deepen Structure-Mechanism Analysis: Utilize advanced techniques like cryo-EM and molecular docking to establish precise structure-mechanism correspondences.
  • Standardize Production: Develop unified national/international standards for extraction, purification, and quality control.
  • Optimize Nanocarrier Design: Create smart, responsive nanocarriers for targeted delivery and controlled release.
  • Expand Clinical Research: Conduct large-scale, multi-center RCTs to validate efficacy and safety in humans.
  • Broaden Application Scope: Explore the potential of polysaccharides in understudied areas like neuroinflammation and tumor-associated inflammation.

Summary updated

Abstract

Chronic excessive inflammation drives the pathogenesis of diseases such as Heart Failure (HF) and arthritis. Natural polysaccharides, with low toxicity and biodegradability, exert anti-inflammatory effects by regulating core inflammatory signaling pathways (e.g., Nuclear Factor-κB (NF-κB), Mitogen-Activated Protein Kinase (MAPK), Toll-Like Receptor (TLR)) and downregulating pro-inflammatory cytokines including Tumor Necrosis Factor-α (TNF-α), IL-1β, and IL-6. But their poor water solubility and easy breakdown by digestive enzymes limit bioavailability. Nanonization solves these problems by enhancing aqueous dispersibility, reducing enzymatic hydrolysis, and improving targeting efficiency (passive via the Enhanced Permeability and Retention (EPR) effect, active via ligand modification). It also strengthens the inhibition of pro-inflammatory pathways, activates the Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2)/Heme Oxygenase-1 (HO-1) antioxidant pathway, and protects the mucosal barrier. This review is divided into four logical sections-fundamental mechanisms of inflammation and polysaccharide regulation, anti-inflammatory activities of natural polysaccharides, nanonization strategies for efficacy enhancement, and clinical translation potential. It eliminates redundancy, integrates overlapping information, and provides a concise framework to promote the clinical application of polysaccharide-based anti-inflammatory therapies.
BibTeX
@inproceedings{yang2025anti,
  author = {Jihao Yang and Kai Xiong and Tianrui Li and M Zhang and Zhangyun Li and Zhili Wen and Yuchuan Jiang},
  title = {{Anti-inflammatory effects of natural polysaccharides: molecular mechanisms and nanotherapeutic applications}},
  booktitle = {Frontiers in Immunology},
  year = {2025},
  doi = {10.3389/fimmu.2025.1723346},
}
Figure